Harmonizing Non-Clinical Evaluation of Microbio...

By João L. Carapinha

March 4, 2026

EMA's Push for Microbiome Medicinal Products Guidance EMA's Non-Clinical Working Party has drafted a concept paper, adopted by CHMP on 16 February 2026, proposing a reflection pap...
CHMP February 2026 Approvals: New Breakthroughs in Medicines and Biosimilars
EMA’s mCombriax Vaccine Recommendation
KEYTRUDA Padcev MIBC Survival: New Era in Treatment Revealed by KEYNOTE-B15 T...
Novartis Drug Discovery Innovation: Advancing Global Health Through Strategic...
BIC LEN HIV Treatment: New Single-Tablet Regimen Shows Promising Results in A...
NICE Approves Ruxolitinib Cream for Treating Vitiligo with Facial Involvement
SAHPRA GMP Compliance: Addressing Allegations Against Adcock Ingram’s C...
Economic Impact of Industry Clinical Trials in Europe
Enhancing Systematic Reviews: AI Literature Review Integration for Efficiency...
Administrative Court Error Complicates Infarmed Vaccine Data Transparency
EMA Validation of ENHERTU Breast Cancer Treatment for Post-Neoadjuvant Therapy
NICE Updates Type 2 Diabetes Guidelines: Emphasizing Cardiorenal Protection w...